Safety and Efficacy Study of VIS649 for IgA Nephropathy

NCT04287985 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A Nephropathy
Glomerular Disease
IgAN

Interventions

DRUG: Dose-Placebo
DRUG: Low Dose-VIS649
DRUG: Medium Dose-VIS649
DRUG: High Dose-VIS649

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.